Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 2
1961 1
1963 1
1974 2
1975 4
1976 7
1977 14
1978 16
1979 25
1980 47
1981 58
1982 65
1983 54
1984 71
1985 60
1986 55
1987 58
1988 82
1989 107
1990 131
1991 130
1992 150
1993 145
1994 149
1995 154
1996 153
1997 147
1998 132
1999 150
2000 147
2001 142
2002 180
2003 186
2004 135
2005 160
2006 161
2007 174
2008 169
2009 165
2010 193
2011 215
2012 233
2013 224
2014 231
2015 243
2016 255
2017 239
2018 257
2019 289
2020 319
2021 263
Text availability
Article attribute
Article type
Publication date

Search Results

6,306 results
Results by year
Filters applied: . Clear all
Page 1
Ursodeoxycholic acid and cancer: From chemoprevention to chemotherapy.
Goossens JF, Bailly C. Goossens JF, et al. Pharmacol Ther. 2019 Nov;203:107396. doi: 10.1016/j.pharmthera.2019.107396. Epub 2019 Jul 26. Pharmacol Ther. 2019. PMID: 31356908 Review.
Ursodeoxycholic acid (UDCA) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. ...
Ursodeoxycholic acid (UDCA) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid b
UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications.
Cabrera D, Arab JP, Arrese M. Cabrera D, et al. Handb Exp Pharmacol. 2019;256:237-264. doi: 10.1007/164_2019_241. Handb Exp Pharmacol. 2019. PMID: 31236688 Review.
In this context, therapeutic approaches for liver diseases using hydrophilic BA (i.e., ursodeoxycholic acid, tauroursodeoxycholic, and, more recently, norursodeoxycholic acid), have been revamped. ...
In this context, therapeutic approaches for liver diseases using hydrophilic BA (i.e., ursodeoxycholic acid, tauroursodeoxycho …
norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Färkkilä M, Schramm C, Spengler U, Chapman R, Bergquist A, Schrumpf E, Nevens F, Trivedi P, Reiter FP, Tornai I, Halilbasic E, Greinwald R, Pröls M, Manns MP, Trauner M; European PSC norUDCA Study Group. Fickert P, et al. J Hepatol. 2017 Sep;67(3):549-558. doi: 10.1016/j.jhep.2017.05.009. Epub 2017 May 18. J Hepatol. 2017. PMID: 28529147 Free article. Clinical Trial.
BACKGROUND & AIM: Primary sclerosing cholangitis (PSC) represents a devastating bile duct disease, currently lacking effective medical therapy. 24-norursodeoxycholic acid (norUDCA) is a side chain-shortened C(23) homologue of UDCA and has shown potent anti-cholestatic, …
BACKGROUND & AIM: Primary sclerosing cholangitis (PSC) represents a devastating bile duct disease, currently lacking effective medical t …
Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed.
Guarino MP, Cocca S, Altomare A, Emerenziani S, Cicala M. Guarino MP, et al. World J Gastroenterol. 2013 Aug 21;19(31):5029-34. doi: 10.3748/wjg.v19.i31.5029. World J Gastroenterol. 2013. PMID: 23964136 Free PMC article. Review.
Since then a large number of investigators all over the world, have been dedicated in biochemical and clinical studies on ursodeoxycholic acid (UDCA), demonstrating its extreme versatility. This editorial is aimed to provide a brief review of recent developments in …
Since then a large number of investigators all over the world, have been dedicated in biochemical and clinical studies on ursodeoxycholic
Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
Paumgartner G, Beuers U. Paumgartner G, et al. Hepatology. 2002 Sep;36(3):525-31. doi: 10.1053/jhep.2002.36088. Hepatology. 2002. PMID: 12198643 Review.
Ursodeoxycholic acid (UCDA) is increasingly used for the treatment of cholestatic liver diseases. Experimental evidence suggests three major mechanisms of action: (1) protection of cholangiocytes against cytotoxicity of hydrophobic bile acids, resulting from modulat
Ursodeoxycholic acid (UCDA) is increasingly used for the treatment of cholestatic liver diseases. Experimental evidence sugges
Ursodeoxycholic acid versus phenobarbital for cholestasis in the Neonatal Intensive Care Unit.
Lewis T, Kuye S, Sherman A. Lewis T, et al. BMC Pediatr. 2018 Jun 20;18(1):197. doi: 10.1186/s12887-018-1167-y. BMC Pediatr. 2018. PMID: 29925342 Free PMC article.
BACKGROUND: Although neonates and young infants with cholestasis are commonly treated with either phenobarbital or ursodeoxycholic acid (ursodiol), there is no evidence that phenobarbital is effective for this indication. Our objective was to compare the effe …
BACKGROUND: Although neonates and young infants with cholestasis are commonly treated with either phenobarbital or ursodeoxycholic
Stability of Compounded Ursodiol Suspensions in PCCA Base, SuspendIt.
Pramar YV, Mandal TK, Bostanian LA, Nguyen AT, Miller V, Morris TC, Graves RA. Pramar YV, et al. Int J Pharm Compd. 2019 Jan-Feb;23(1):70-76. Int J Pharm Compd. 2019. PMID: 30668538
Ursodiol (ursodeoxycholic acid) is a nontoxic, naturally occurring bile acid that constitutes 1% to 2% of human bile. ...A robust, stability-indicating high-performance liquid chromatographic assay for the determination of the chemical stability of
Ursodiol (ursodeoxycholic acid) is a nontoxic, naturally occurring bile acid that constitutes 1% to 2% of human
Ursodiol in patients with parenteral nutrition-associated cholestasis.
San Luis VA, Btaiche IF. San Luis VA, et al. Ann Pharmacother. 2007 Nov;41(11):1867-72. doi: 10.1345/aph.1K229. Epub 2007 Oct 2. Ann Pharmacother. 2007. PMID: 17911205 Free article. Review.
OBJECTIVE: To review the role of ursodeoxycholic acid (ursodiol) in treating parenteral nutrition-associated cholestasis (PNAC). DATA SOURCES: A MEDLINE (1950-May 2007) search was performed using the key terms parenteral nutrition, cholestasis, ursodeoxych
OBJECTIVE: To review the role of ursodeoxycholic acid (ursodiol) in treating parenteral nutrition-associated cholestasi …
Ursodiol for hepatobiliary disorders.
Rubin RA, Kowalski TE, Khandelwal M, Malet PF. Rubin RA, et al. Ann Intern Med. 1994 Aug 1;121(3):207-18. doi: 10.7326/0003-4819-121-3-199408010-00009. Ann Intern Med. 1994. PMID: 8017748 Review.
PURPOSE: To explain the rationale supporting the use of ursodiol (ursodeoxycholic acid) for the treatment of patients with cholesterol gallstones and chronic liver diseases and to describe the results obtained in clinical trials. ...DATA SYNTHESIS: Ursodio
PURPOSE: To explain the rationale supporting the use of ursodiol (ursodeoxycholic acid) for the treatment of patients w …
[Bile acids in arrhythmia].
Yan JJ, Fan HQ, Yang L. Yan JJ, et al. Zhonghua Gan Zang Bing Za Zhi. 2020 Apr 20;28(4):361-364. doi: 10.3760/cma.j.cn501113-20190308-00074. Zhonghua Gan Zang Bing Za Zhi. 2020. PMID: 32403891 Review. Chinese.
Ursodeoxycholic acid (UDCA) is currently found to have protective effect on the heart and has an antiarrhythmic effect. This article mainly reviews the function and mechanism of bile acid in arrhythmia....
Ursodeoxycholic acid (UDCA) is currently found to have protective effect on the heart and has an antiarrhythmic effect. This a
6,306 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page